Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial - PubMed
4 hours ago
- #Chemoembolization
- #Immunotherapy
- #Hepatocellular Carcinoma
- The study compared TACE combined with camrelizumab and rivoceranib (TACE-C-R) versus TACE alone in unresectable HCC.
- Median progression-free survival (PFS) was significantly longer with TACE-C-R (10.8 months) compared to TACE alone (3.2 months).
- Grade ≥3 treatment-related adverse events were more common with TACE-C-R (74.5%) than with TACE alone (22.3%).
- The most common adverse events were increased AST and ALT levels.
- The combination therapy showed a manageable safety profile and statistically significant improvement in PFS.